Celgene (CELG) -10.2% after EU regulators request more data about widening authorization of the...

|About: Celgene Corporation (CELG)|By:, SA News Editor

Celgene (CELG) -10.2% after EU regulators request more data about widening authorization of the firm's multiple myeloma treatment Revlimid to treat newly diagnosed patients and as a maintenance therapy. Celgene is pulling the submission and will resubmit it with more data, and the firm is "re-evaluating" a similar FDA application. (PR)